(Q37803240)

23 August 2017

title

Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V). (English)

1 reference

23 August 2017

1 reference

1 reference

Patrick Biggar

1

1 reference

23 August 2017

Markus Ketteler

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

16

1 reference

23 August 2017

page(s)

2739-2750

1 reference

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

The phosphatonin pathway: new insights in phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

The role of phosphate in the action of vitamin D on the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Growth hormone and parathyroid hormone stimulate intestinal calcium absorption in aged female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Does PTH have a direct effect on intestine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Calcification and cardiovascular health: new insights into an old phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Noncompliance in hemodialysis: predictors and survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Vascular calcification: in vitro evidence for the role of inorganic phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Vascular calcification and cardiovascular function in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Pathophysiology of vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Phosphate regulation of vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Dialysis dose and frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Should the medicare ESRD program pay for daily dialysis? An ethical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

21 January 2018

Oral phosphate binders

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Novel dosage forms and regimens for sevelamer-based phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Sevelamer, a phosphate-binding polymer, is a non-absorbed compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Safety of new phosphate binders for chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Bile acid binding to sevelamer HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Oral calcium, sevelamer and vascular calcification in uraemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Determinants of progressive vascular calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

Economic evaluation of sevelamer in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.526107

10.1517/14656566.2010.526107

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3cxpucqh7fe53nnebehtix3svm

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_3cxpucqh7fe53nnebehtix3svm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3cxpucqh7fe53nnebehtix3svm

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/3cxpucqh7fe53nnebehtix3svm

1 reference